Mobilized Peripheral Blood Stem Cells are Pluripotent and Can Be Safely Harvested and Stored for Cartilage Repair
| Autor: | Travis J. Dekker, Kevin B. Johnson, Khay-Yong Saw, Johnny Torres, Adam W. Anz, Hillary A. Plummer, Caroline Siew-Yoke Jee |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Colony-forming unit
030222 orthopedics business.industry medicine.medical_treatment CD34 Reproducibility of Results Stem-cell therapy 030204 cardiovascular system & hematology Filgrastim Vial Cryopreservation Andrology Colony-Forming Units Assay 03 medical and health sciences 0302 clinical medicine Apheresis Cartilage medicine Blood Component Removal Peripheral Blood Stem Cells Humans Orthopedics and Sports Medicine Stem cell business medicine.drug |
| Zdroj: | Arthroscopy : the journal of arthroscopicrelated surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 37(11) |
| ISSN: | 1526-3231 |
| Popis: | Purpose The primary objective of this study was to reproduce and validate the harvest, processing and storage of peripheral blood stem cells for a subsequent cartilage repair trial, evaluating safety, reliability, and potential to produce viable, sterile stem cells. Methods Ten healthy subjects (aged 19-44 years) received 3 consecutive daily doses of filgrastim followed by an apheresis harvest of mononuclear cells on a fourth day. In a clean room, the apheresis product was prepared for cryopreservation and processed into 4 mL aliquots. Sterility and qualification testing were performed pre-processing and post-processing at multiple time points out to 2 years. Eight samples were shipped internationally to validate cell transport potential. One sample from all participants was cultured to test proliferative potential with colony forming unit (CFU) assay. Five samples, from 5 participants were tested for differentiation potential, including chondrogenic, adipogenic, osteogenic, endoderm, and ectoderm assays. Results Fresh aliquots contained an average of 532.9 ± 166. × 106 total viable cells/4 mL vial and 2.1 ± 1.0 × 106 CD34+ cells/4 mL vial. After processing for cryopreservation, the average cell count decreased to 331.3 ± 79. × 106 total viable cells /4 mL vial and 1.5 ± 0.7 × 106 CD34+ cells/4 mL vial CD34+ cells. Preprocessing viability averaged 99% and postprocessing 88%. Viability remained constant after cryopreservation at all subsequent time points. All sterility testing was negative. All samples showed proliferative potential, with average CFU count 301.4 ± 63.9. All samples were pluripotent. Conclusions Peripheral blood stem cells are pluripotent and can be safely harvested/stored with filgrastim, apheresis, clean-room processing, and cryopreservation. These cells can be stored for 2 years and shipped without loss of viability. Clinical Relevance This method represents an accessible stem cell therapy in development to augment cartilage repair. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|